A Pilot Study of Nivolumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 14 Sep 2018 Last checked against ClinicalTrials.gov record.
- 06 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 06 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.